Biopharma News

Zymeworks has entered into a licensing and collaboration agreement with ImClone Systems to develop novel bi-specific antibody oncology therapeutics.

Genzyme plans to appeal FDA?s decision that the multiple-sclerosis treatment is not ready for approval.

Pfizer appoints management changes to take effect in 2014.

Siemens enters agreement with Pfizer to commercialize diagnostic tests for therapeutic products across Pfizer's pipeline.

ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.

AstraZeneca's MedImmune will collaborate with Johns Hopkins University in both biologics and small-molecule projects.

Merck's new facility for aseptic production in Reinbek, Germany is scheduled to be completed in 2016.

Johnson&Johnson will open a network of partnering offices across the UK.

Octapharma and Pfizer form an agreement for the future marketing and commercialization of human prothrombin complex concentrate.

Bristol-Myers Squibb has elected Thomas Lynch, Jr., MD to its board of directors.

The Indiana Biosciences Research Institute will accelerate collaboration and focus on human-health solutions.

Additional companies join Merck KGaA and Neviah Genomics in the Israel BioIncubator.

Merck KGaA plans to build a new biomanufacturing facility in Nantong, China.

Shire's agreement to acquire ViroPharma will strengthen its rare-disease portfolio.

ISPE names Novartis' US Flu Cell Culture facility as award winner.

KaloBios Pharmaceuticals receives FDA Orphan Drug Designation for KB001-A in treatment of cystic fibrosis patients.

GSK and the Gates Foundation will invest a combined $1.8 million in early stage research into vaccine thermostability.

Zhoydro ER is the first drug to have updated labeling now required for all ER/LA opioid analgesics.

Big pharma companies Novartis, Amgen, and Bristol-Myers Squibb announce positive third-quarter 2013 results.

Amarin cuts staff in half after an FDA committee rejects its product label expansion.

Abbott?s third-quarter 2013 global sales increased slightly but were affected by a disruption in the International Nutrition business.

J&J announces 2013 third-quarter sales increased 3% over 2012 third-quarter sales.

MedImmune expands its antibody-drug conjugate capability through acquisition and collaboration.

GlaxoSmithKline?s sale of its thrombosis brands is part of a focus on its late-stage pipeline.

Merck announced plans to reduce its workforce by 8,500 and move its headquarters in order to sharpen its commercial and R&D focus.

Merck & Co. has received a Complete Response Letter from FDA for the resubmission of its new drug application for sugammadex sodium injection.

J&J's Janssen and PATH partner to improve drug formulation that could help prevent HIV infection.

Cell Medica, a T cell therapeutics company, has opened a European manufacturing facility in Berlin-Buch, Germany to develop, manufacture, and market treatments of infections and cancers related to oncogenic viruses.